NCT00537342

Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)

Prospective, Randomised, Double Blind, Placebo Controlled Study of Treatment With Sublingual Immunotherapy of Depigmented and Polymerised Allergen Extract of O. Europaea in Two Groups of Patients With Allergic Rhinitis /Rhinoconjunctivitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 83 (actual)
• Sponsor: Laboratorios Leti, S.L. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract of Olea europaea in the rhinitis or allergic rhinoconjunctivitis

Detailed description

Immunotherapy is a specific treatment for allergic diseases. Unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. This is a prospective double-blind placebo controlled study with two arms of treatment: placebo and active.

Conditions

• Allergy
• Rhinoconjunctivitis

Interventions

Type	Name	Description
BIOLOGICAL	Immunotherapy with modified extract of O. europaea pollen	Sublingual (2 drops daily during 2 months)

Timeline

• Start date: 2007-10-01
• Primary completion: 2009-09-01
• Completion: 2009-12-01
• First posted: 2007-10-01
• Last updated: 2010-12-17

Locations

1 site across 1 country: Spain